Sapacitabine
 | |
| Systematic (IUPAC) name | |
|---|---|
| 1-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-4-(palmitoylamino)pyrimidin-2(1H)-one | |
| Clinical data | |
| Identifiers | |
151823-14-2  | |
| None | |
| PubChem | CID 153970 |
| ChemSpider |
135703  |
| UNII |
W335P73C3L |
| Synonyms | N-[1-[(2R,3S,4S,5R)-3-Cyano-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]hexadecanamide |
| Chemical data | |
| Formula | C26H42N4O5 |
| 490.64 g/mol | |
|
SMILES
| |
| |
| (what is this?) (verify) | |
Sapacitabine is a drug undergoing research for potential use in chemotherapy.[1][2]
Sapacitabine is an oral nucleoside analog prodrug that acts through a dual mechanism. The compound interferes with DNA synthesis by causing single-strand DNA breaks and induces arrest of the cell division cycle at G2 phase.
Both sapacitabine and its major metabolite, CNDAC, have demonstrated potent anti-tumor activity in both blood and solid tumors in preclinical studies. In a liver metastatic mouse model, sapacitabine was shown to be superior to gemcitabine (Gemzar; Lilly) or 5-FU, two widely used nucleoside analogs, in delaying the onset and growth of liver metastasis.
Clinical trials
Cyclacel has initiated a number of clinical trials to evaluate sapacitabine in both solid and hematological tumors laying the foundation for future Phase 2 studies and combination studies with other anti-cancer agents. Three Phase 1 studies have been completed, which evaluated safety and pharmacokinetics of a variety of dosing schedules in approximately 120 patients with solid tumors.
Sapacitabine is currently being evaluated in two Phase 2 trials in patients with advanced cutaneous T-cell lymphoma (CTCL) and in elderly patients with acute myeloid leukemias (AML).
As of February 2013 it is in a phase 3 trial for AML.[3]
References
- ↑ Faderl S, Gandhi V, Kantarjian HM (March 2008). "Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia". Curr. Opin. Hematol. 15 (2): 101–7. doi:10.1097/MOH.0b013e3282f46e94. PMID 18300755.
- ↑ Serova M, Galmarini CM, Ghoul A et al. (September 2007). "Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells". Br. J. Cancer 97 (5): 628–36. doi:10.1038/sj.bjc.6603896. PMC 2360357. PMID 17637678.
- ↑ Patents-re-use-with-HDIs
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||